Your browser doesn't support javascript.
loading
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.
Earl, Helena M; Vallier, Anne-Laure; Hiller, Louise; Fenwick, Nicola; Young, Jennie; Iddawela, Mahesh; Abraham, Jean; Hughes-Davies, Luke; Gounaris, Ioannis; McAdam, Karen; Houston, Stephen; Hickish, Tamas; Skene, Anthony; Chan, Stephen; Dean, Susan; Ritchie, Diana; Laing, Robert; Harries, Mark; Gallagher, Christopher; Wishart, Gordon; Dunn, Janet; Provenzano, Elena; Caldas, Carlos.
Afiliación
  • Earl HM; University of Cambridge, Department of Oncology, Addenbrooke's Hospital, Hills Road, Cambridge, UK; National Institute for Health Research, Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Hills Road, Cambridge, UK; Department of Oncology, Cambridge Cancer Tria
  • Vallier AL; Department of Oncology, Cambridge Cancer Trials Centre, Addenbrooke's Hospital, Cambridge, UK; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, UK.
  • Hiller L; Warwick Clinical Trials Unit, University of Warwick, Gibbet Hill Road, Coventry, UK. Electronic address: L.Hiller@warwick.ac.uk.
  • Fenwick N; Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, UK.
  • Young J; Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, UK.
  • Iddawela M; University of Melbourne, Shepparton, VIC, Australia.
  • Abraham J; National Institute for Health Research, Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Hills Road, Cambridge, UK; Department of Oncology, Cambridge Cancer Trials Centre, Addenbrooke's Hospital, Cambridge, UK; Cambridge Breast Unit and Cambridge University Hos
  • Hughes-Davies L; Department of Oncology, Cambridge Cancer Trials Centre, Addenbrooke's Hospital, Cambridge, UK; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, UK.
  • Gounaris I; CancerResearch UK Cambridge Institute, Cambridge, UK.
  • McAdam K; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, UK; Peterborough and Stamford Hospitals NHS Foundation Trust and Cambridge University Hospital NHS Foundation Trust, UK.
  • Houston S; Royal Surrey County Hospital NHS Foundation Trust, Egerton Road, Guildford, UK.
  • Hickish T; Royal Bournemouth Hospital, Castle Lane East, Bournemouth, UK.
  • Skene A; Department of Surgery, Royal Bournemouth Hospital, Castle Lane East, Bournemouth, UK.
  • Chan S; Nottingham City Hospital, Hucknall Road, Nottingham, UK.
  • Dean S; Dorset Cancer Centre, Poole Hospital NHS Trust, Poole, UK.
  • Ritchie D; Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, UK.
  • Laing R; Royal Surrey County Hospital NHS Foundation Trust, Egerton Road, Guildford, UK.
  • Harries M; Breast Oncology Unit, Thomas Guy House, Guys Hospital, St Thomas Street, London, UK.
  • Gallagher C; Department of Medical Oncology, St Bartholomew's Hospital, West Smithfield, London, UK.
  • Wishart G; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, UK.
  • Dunn J; Warwick Clinical Trials Unit, University of Warwick, Gibbet Hill Road, Coventry, UK.
  • Provenzano E; National Institute for Health Research, Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Hills Road, Cambridge, UK; Department of Oncology, Cambridge Cancer Trials Centre, Addenbrooke's Hospital, Cambridge, UK; Cambridge Breast Unit and Cambridge University Hos
  • Caldas C; University of Cambridge, Department of Oncology, Addenbrooke's Hospital, Hills Road, Cambridge, UK; National Institute for Health Research, Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Hills Road, Cambridge, UK; Department of Oncology, Cambridge Cancer Tria
Lancet Oncol ; 15(2): 201-12, 2014 Feb.
Article en En | MEDLINE | ID: mdl-24360787
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Terapia Neoadyuvante Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2014 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Terapia Neoadyuvante Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2014 Tipo del documento: Article